Robert Botta, MD
Vascular Surgery · Watertown, CTNPI 1780094326
Payments from drug & device makers
What this record shows
This record is dominated by other: $36,583 of the $50,197 with a category attached, or 72.9%. Angiodynamics, Inc. accounts for 73.2% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2023 at $18,780 and has fallen 65.9% since, to $6,398 in 2025.
Across 184 payments — averaging $272.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$37K
- Cardiovascular Systems Inc.$6K
- Boston Scientific$1K
- Inari Medical, Inc.$1K
- Medtronic$1K
- Silk Road Medical, Inc.$447
- plus $3K from 28 others
What the payments were for
- Consulting fees$4,2759%
- Travel & lodging$1,3773%
- Food & beverage$7,96116%
- Other$36,58373%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 10 | $36,758 |
| Cardiovascular Systems Inc. | 14 | $6,250 |
| Boston Scientific | 32 | $1,471 |
| Inari Medical, Inc. | 19 | $1,350 |
| Medtronic(2 entities) | 29 | $1,269 |
| Silk Road Medical, Inc. | 6 | $447 |
| Endologix LLC | 5 | $387 |
| Reapplix Inc. | 4 | $325 |
| Stryker | 5 | $271 |
| Johnson & Johnson | 8 | $227 |
| Lemaitre Vascular, Inc. | 5 | $196 |
| E.r. Squibb & Sons, L.L.C. | 8 | $174 |
| Penumbra, Inc. | 1 | $147 |
| Pfizer | 7 | $141 |
| CSL Behring | 1 | $125 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $73 |
| Solventum Corporation | 3 | $72 |
| Abbott | 2 | $64 |
| Smith+Nephew | 3 | $62 |
| Tactile Systems Technology Inc | 2 | $50 |
| Cardiva Medical, Inc. | 2 | $47 |
| Organogenesis Inc. | 2 | $36 |
| Bard Peripheral Vascular, Inc. | 1 | $34 |
| Cordis US CORP. | 2 | $33 |
| Cook Medical LLC | 2 | $30 |
| Next Science LLC | 2 | $20 |
| Cagent Vascular Inc | 1 | $19 |
| Mimedx Group, Inc. | 1 | $19 |
| Convatec Inc. | 1 | $19 |
| Shockwave Medical, Inc | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Reprise Biomedical, Inc. | 1 | $18 |
| Biotronik Inc. | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$36,718
- Diamondback Peripheral$5,980
- FLOWTRIEVER CATHETER, S$1,150
- CT THROMBECTOMY SYSTEM KIT$1,150
- ENROUTE Transcarotid Neuroprotection System$492
- ENROUTE Transcarotid Stent$328
- 3C Patch Kit - Box$285
- Endurant$245
- Alto Abdominal Stent Graft System$195
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$164
- Indigo System$147
- EKOSONIC$142
- ARTIX MT$140
- ELUVIA$128
- Kcentra$125
- ARTEGRAFT VASCULAR GRAFT$124
- GENERAL VASCULAR INTERVENTION$117
- ENDURANT IIS$102
How this compares
$50,197 in reported general payments places this provider in the 85th percentile of 82 vascular surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 40 | $40,331 |
| EliquisApixaban | 12 | $18,322 |
| ClopidogrelClopidogrel Bisulfate | 129 | $1,154 |
| Gabapentin | 14 | $256 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $96 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $227 | $40,33140 claims |
| PfizerEliquis | $141 | $18,32212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 82 vascular surgery providers in Connecticut.
Other vascular surgery in Watertown
- Jaime StrachanWatertown$28K
- Moqueet QureshiWatertown$23K
- Uwe FischerNew London$941K
- Paul GagneDarien$766K
- Naiem NassiriNew Haven$348K
- Lee GoldsteinStratford$272K
- Mohiuddin CheemaHartford$228K
- Bauer SumpioNew Haven$205K
- Javairiah FatimaDanbury$152K
- Bart MuhsOld Saybrook$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.